Has Nilesh Vora, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,382 in general payments to Nilesh Vora, MD across 249 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nilesh Vora, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nilesh Vora, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nilesh Vora, MD

Hematology & Oncology · Long Beach, CANPI 1790976363

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Merck at 52.1% of the total. 2025 is the largest year on record at $14,481, 3.5 times the $4,081 reported in 2019.

$25,382in general payments, 2019–2025

Across 249 payments — averaging $101.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$13K
AstraZeneca$4K
Regeneron Healthcare Solutions, Inc.$2K
Johnson & Johnson$1K
E.r. Squibb & Sons, L.L.C.$896
Genentech USA, Inc.$358
plus $4K from 41 others

$1,794,806in research payments, 2019–2025

Across 57 payments — averaging $31,488 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mirati Therapeutics, Inc.$1.1M
Merck$606K
Novocure GmbH$52K
AstraZeneca$49K
Halozyme Inc$1K
E.r. Squibb & Sons, L.L.C.$89

What the payments were for

Consulting fees$4,63818%
Speaking & faculty fees$11,52045%
Travel & lodging$1,4746%
Food & beverage$7,55430%
Education$1961%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	35	$13,221
AstraZeneca(2 entities)	17	$4,129
Regeneron Healthcare Solutions, Inc.	4	$2,025
Johnson & Johnson(3 entities)	43	$1,192
E.r. Squibb & Sons, L.L.C.	25	$896
Genentech USA, Inc.	14	$358
Bristol Myers Squibb	12	$352
Amgen	10	$313
Tempus AI, Inc	4	$231
Incyte Corporation	9	$210
Novartis	7	$195
Medtronic	1	$167
Dendreon Pharmaceuticals LLC	1	$148
Janssen Scientific Affairs, LLC	2	$141
Beone Medicines USA, Inc.	4	$133
Bayer	5	$117
Sirtex Medical Inc	3	$110
Lilly USA, LLC	5	$110
Karyopharm Therapeutics Inc.	1	$91
Puma Biotechnology, Inc.	3	$90
Sumitomo Pharma America, Inc.	3	$88
Ipsen Biopharmaceuticals, Inc	3	$79
Sanofi	3	$76
AbbVie	3	$74
Pfizer	4	$71
Sanofi-aventis U.S. LLC	1	$67
Seagen Inc.	2	$62
Agios Pharmaceuticals, Inc.	2	$57
Daiichi Sankyo Inc.	2	$52
Rigel Pharmaceuticals, Inc.	2	$49
Deciphera Pharmaceuticals Inc.	1	$48
Epizyme, Inc.	1	$45
Takeda Pharmaceuticals U.S.A., Inc.	1	$38
Chiesi USA, Inc.	2	$34
Gilead	1	$34
Jazz Pharmaceuticals Inc.	1	$33
AVEO Pharmaceuticals, Inc.	1	$30
Mirati Therapeutics, Inc.	2	$30
Pharmacyclics LLC, An Abbvie Company	1	$28
Sun Pharmaceutical Industries Inc.	1	$23
Boehringer Ingelheim	1	$23
Coherus Oncology, Inc.	1	$22
Genmab U.S., Inc.	1	$20
Acceleron Pharma, Inc.	1	$19
GSK	1	$19
Azurity Pharmaceuticals, Inc.	1	$17
Eisai Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,382 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024

$169,768

Medicare patients

319

Services billed

1,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Megestrol Acetate	14	$861
Tamoxifen Citrate	13	$304
Anastrozole	11	$226
Ondansetron Hcl	11	$61

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Long Beach

Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M
Robert VescioWest Hollywood$1.1M
Kevin KellyLos Angeles$894K
Johnny ChangEncino$884K
Nitin RohatgiSacramento$814K
Omid HamidSanta Monica$809K
Catherine CoombsOrange$786K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →